Jaguar Health, Inc. (JAGX)
JAGX Stock Price Chart
Explore Jaguar Health, Inc. interactive price chart. Choose custom timeframes to analyze JAGX price movements and trends.
JAGX Company Profile
Discover essential business fundamentals and corporate details for Jaguar Health, Inc. (JAGX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 May 2015
Employees
49.00
Website
https://jaguar.healthCEO
Lisa A. Conte
Description
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
JAGX Financial Timeline
Browse a chronological timeline of Jaguar Health, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$5.08, while revenue estimate is $3.73M.
Earnings released on 14 Aug 2025
EPS came in at -$10.26 falling short of the estimated -$5.08 by -101.97%, while revenue for the quarter reached $2.98M , missing expectations by -20.13%.
Earnings released on 15 May 2025
EPS came in at -$16.70 surpassing the estimated -$18.00 by +7.22%, while revenue for the quarter reached $2.17M , missing expectations by -33.61%.
Earnings released on 7 Apr 2025
EPS came in at -$0.34 surpassing the estimated -$18.50 by +98.16%, while revenue for the quarter reached $3.51M , beating expectations by +12.11%.
Stock split effective on 24 Mar 2025
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Nov 2024
EPS came in at -$26.25 falling short of the estimated -$2.37 by -1.01K%, while revenue for the quarter reached $3.11M , missing expectations by -21.12%.
Earnings released on 13 Aug 2024
EPS came in at -$101.00 falling short of the estimated -$1.20 by -8.32K%, while revenue for the quarter reached $2.72M , missing expectations by -20.44%.
Stock split effective on 23 May 2024
Shares were split 1 : 60 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 May 2024
EPS came in at -$90.36 falling short of the estimated -$38.73 by -133.33%, while revenue for the quarter reached $2.35M , beating expectations by +2.22%.
Earnings released on 1 Apr 2024
EPS came in at -$594.64 surpassing the estimated -$1.47K by +59.55%, while revenue for the quarter reached $2.30M , missing expectations by -11.88%.
Earnings released on 14 Nov 2023
EPS came in at -$572.29 falling short of the estimated -$1.23 by -46.43K%, while revenue for the quarter reached $2.81M , beating expectations by +7.78%.
Earnings released on 14 Aug 2023
EPS came in at -$632.53 falling short of the estimated -$1.53 by -41.24K%, while revenue for the quarter reached $2.68M , missing expectations by -17.91%.
Earnings released on 15 May 2023
EPS came in at -$3.60K surpassing the estimated -$6.75K by +46.68%, while revenue for the quarter reached $1.97M , missing expectations by -39.51%.
Earnings released on 28 Apr 2023
EPS came in at -$631.13K , while revenue for the quarter reached $3.26M .
Stock split effective on 23 Jan 2023
Shares were split 1 : 75 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2022
EPS came in at -$13.59K falling short of the estimated -$5.62 by -241.68K%, while revenue for the quarter reached $3.15M , missing expectations by -11.27%.
Earnings released on 22 Aug 2022
EPS came in at -$13.59K falling short of the estimated -$16.50 by -82.25K%, while revenue for the quarter reached $2.92M , missing expectations by -5.77%.
Earnings released on 10 May 2022
EPS came in at -$45.29K falling short of the estimated -$12.75 by -355.15K%, while revenue for the quarter reached $2.63M , beating expectations by +64.06%.
Earnings released on 11 Mar 2022
EPS came in at -$35.10K falling short of the estimated -$6.75 by -519.94K%, while revenue for the quarter reached $2.08M , missing expectations by -75.24%.
Earnings released on 17 Nov 2021
EPS came in at -$30.57K falling short of the estimated -$12.75 by -239.69K%, while revenue for the quarter reached $630.00K , missing expectations by -77.26%.
Stock split effective on 8 Sept 2021
Shares were split 1 : 3 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Aug 2021
EPS came in at -$33.97K falling short of the estimated -$3.00 by -1.13M%, while revenue for the quarter reached $385.00K , meeting expectations.
Earnings released on 17 May 2021
EPS came in at -$33.97K falling short of the estimated -$1.50 by -2.26M%, while revenue for the quarter reached $1.24M , missing expectations by -62.96%.
Earnings released on 31 Mar 2021
EPS came in at -$33.75 falling short of the estimated -$22.50 by -50.00%, while revenue for the quarter reached $2.58M .
Earnings released on 16 Nov 2020
EPS came in at -$71.35K falling short of the estimated -$8.25 by -864.69K%, while revenue for the quarter reached $2.77M , beating expectations by +31.69%.
JAGX Stock Performance
Access detailed JAGX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.